Ixazomib: a novel drug for multiple myeloma

Expert Review of Hematology
Saurabh ZanwarPrashant Kapoor

Abstract

Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.

References

Dec 3, 2002·Nature Reviews. Cancer·Teru Hideshima, Kenneth C Anderson
Jan 17, 2003·Mayo Clinic Proceedings·Robert A KylePhilip R Greipp
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jul 13, 2004·Mayo Clinic Proceedings·Shaji K KumarPhilip R Greipp
Aug 19, 2007·Cancer Cell·Thomas D Gilmore
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Jun 10, 2008·Current Opinion in Hematology·Zhi-Wei LiJames R Berenson
Jan 16, 2009·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Keiji Tanaka
Oct 5, 2010·Oncotarget·Yulia N Demchenko, W Michael Kuehl
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk
Jul 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dharminder ChauhanKenneth C Anderson
Sep 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Edmund C LeeSiegfried Janz
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Jul 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claire FabreKenneth C Anderson
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Dec 30, 2014·Pharmaceuticals·Noah M Merin, Kevin R Kelly
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
May 4, 2015·Biochemical Pharmacology·Beverly A Teicher, Joseph E Tomaszewski
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Nov 22, 2015·Expert Review of Anticancer Therapy·Massimo OffidaniPietro Leoni
Feb 6, 2016·Drugs·Matt Shirley
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Jul 14, 2016·British Journal of Haematology·Kwee YongMichele Cavo
Jul 30, 2016·Blood Cancer Journal·A M Rajan, S Kumar
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators

❮ Previous
Next ❯

Citations

Feb 2, 2020·Current Hematologic Malignancy Reports·Saurabh ZanwarPrashant Kapoor
Mar 2, 2019·Current Hematologic Malignancy Reports·Saurabh ZanwarPrashant Kapoor
Oct 13, 2020·Hematology Reports·Daniele DerudasClaudio Cerchione
Apr 30, 2021·Organic & Biomolecular Chemistry·Dipti LaiAlakananda Hajra
Jun 1, 2021·Signal Transduction and Targeted Therapy·Lei ZhongShengyong Yang
Nov 12, 2021·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios Athanasios Dimopoulos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Drug Safety
Antoine Bonnet, Philippe Moreau
Expert Opinion on Pharmacotherapy
Emilia ScalzulliMaria Teresa Petrucci
Expert Opinion on Drug Safety
Danielle SchlaferSagar Lonial
Expert Opinion on Investigational Drugs
Massimo GentileSilvia Gentili
© 2022 Meta ULC. All rights reserved